GMPharm SRL
GMPharm reported total assets of 215,626 € at the end of the 2025 financial year (annual accounts filed with the NBB on 30 Apr 2026).
The score of GMPharm shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +537 % Total assets +389 %
Accounts of the company itself (not consolidated).
The full file covers 4 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
GMPharm's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 30 Apr 2026
- Year ended 31 Dec 2024filed on 26 Jun 2025
- Year ended 31 Dec 2023filed on 07 Jun 2024
- Year ended 31 Dec 2022filed on 30 Jun 2023
GMPharm's financial analysis
- Solvency81.2%sector median: 58.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of GMPharm
GMPharm's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0781.862.362
- VAT number
- BE0781862362
- Peppol
- Registered · 0208:0781862362 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 11 Feb 2022
- Registered office
- 1360 Perwez
- Latest accounts
- 2025 · filed on 30 Apr 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
GMPharm (SRL) has been based in Perwez since 2022, active in: research and experimental development on biotechnology. For 2025, it reports a net profit of 55,459 € and equity of 175,058 €; its revenue is not published. Its solvency stands at 81.2%, above the median of its sector (58.2%).
Companies similar to GMPharm
Companies in the same business, of comparable size and area, outside its group.
- NanoBiotech Research and experimental development on natural sciences and engineering Diepenbeek · balance sheet 1,834 €
- Ceperitus Research and experimental development on natural sciences and engineering Ghent · balance sheet 217,514 €
- STXC Research and experimental development on natural sciences and engineering Aalst · balance sheet 210,455 €
- TereLabs Research and experimental development on natural sciences and engineering Brussels · balance sheet 207,737 €
- Hephaistos-Belgium Research and experimental development on natural sciences and engineering Liège · balance sheet 242,189 €
- Arquebus Solutions Europe Research and experimental development on natural sciences and engineering Machelen (Brab.) · balance sheet 186,058 €
- OCTIMET Oncology Research and experimental development on natural sciences and engineering Geel · balance sheet 252,753 €
- ImmuneWatch Research and experimental development on natural sciences and engineering Antwerp · balance sheet 173,740 €
Frequently asked questions about GMPharm
What is the revenue of GMPharm?
GMPharm files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of GMPharm?
In Belgium, the VAT number is the company number prefixed with BE: BE0781862362 for GMPharm, if the company is VAT-registered. Its company number (CBE) is 0781.862.362.
Where is the registered office of GMPharm?
According to the CBE register, the registered office of GMPharm is in 1360 Perwez.
What is the equity of GMPharm?
At the close of the 2025 financial year, the equity of GMPharm amounts to 175,058 €, a solvency of 81.2% of total assets.
Who manages GMPharm?
The register lists 2 active mandates at GMPharm. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of GMPharm
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →